{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:44:53Z","timestamp":1780523093652,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several studies investigated the effectiveness and the safety of different doses of pregabalin in fibromyalgia. However, the optimal protocol remains controversial. A Bayesian network meta-analysis comparing 300, 450, and 600\u00a0mg\/daily of pregabalin for fibromyalgia was conducted. The literature search was conducted in January 2022. All the double-blind randomised clinical trials comparing two or more dose protocols of pregabalin for fibromyalgia were accessed. Studies enrolling less than 50 patients were not eligible, nor were those with a length of follow-up shorter than eight weeks. The outcomes of interests were: Fibromyalgia Impact Questionnaire (FIQ), sleep quality, and adverse events. The network meta-analyses were performed using the routine for Bayesian hierarchical random-effects model analysis, with log odd ratio (LOR) and standardized mean difference (SMD) effect measure. Data from 4693 patients (mean age 48.5\u00a0years) were retrieved. 93.1% (4370 of 4693 patients) were women. The median follow-up was 14.8\u00a0weeks. Pregabalin 450\u00a0mg\/daily resulted in greater reduction in Fibromyalgia Impact Questionnaire (SMD \u2212\u00a01.83). Pregabalin 600 demonstrated the greatest sleep quality (SMD 0.15). Pregabalin 300\u00a0mg\/daily evidenced the lowest rate of adverse events (LOR 0.12). The dose of pregabalin must be customised according to patients\u2019 characteristics and main symptoms.<\/jats:p>","DOI":"10.1038\/s41598-022-16146-x","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:07:32Z","timestamp":1657904852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-1221","authenticated-orcid":false,"given":"Filippo","family":"Migliorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maffulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Knobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Tenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aljalloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Colarossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"7","key":"16146_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s10067-017-3595-8","volume":"36","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. The placebo effect and its determinants in fibromyalgia: Meta-analysis of randomised controlled trials. Clin. Rheumatol. 36(7), 1623\u20131630. https:\/\/doi.org\/10.1007\/s10067-017-3595-8 (2017).","journal-title":"Clin. Rheumatol."},{"key":"16146_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/426130","volume":"2012","author":"E Bellato","year":"2012","unstructured":"Bellato, E. et al. Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and treatment. Pain Res. Treat. 2012, 426130. https:\/\/doi.org\/10.1155\/2012\/426130 (2012).","journal-title":"Pain Res. Treat."},{"issue":"5","key":"16146_CR3","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC202003030","volume":"172","author":"MJ Bair","year":"2020","unstructured":"Bair, M. J. & Krebs, E. E. Fibromyalgia. Ann. Intern. Med. 172(5), ITC33\u2013ITC48. https:\/\/doi.org\/10.7326\/AITC202003030 (2020).","journal-title":"Ann. Intern. Med."},{"key":"16146_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jor.2020.01.013","volume":"20","author":"M Hatami","year":"2020","unstructured":"Hatami, M. et al. Association of catechol-O-methyltranferase 472G>A (Val158Met) polymorphism with susceptibility to fibromyalgia syndrome. J. Orthop. 20, 257\u2013260. https:\/\/doi.org\/10.1016\/j.jor.2020.01.013 (2020).","journal-title":"J. Orthop."},{"issue":"5","key":"16146_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.mayocp.2015.03.014","volume":"90","author":"DJ Clauw","year":"2015","unstructured":"Clauw, D. J. Fibromyalgia and related conditions. Mayo Clin. Proc. 90(5), 680\u2013692. https:\/\/doi.org\/10.1016\/j.mayocp.2015.03.014 (2015).","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"16146_CR6","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/art.24849","volume":"60","author":"RE Harris","year":"2009","unstructured":"Harris, R. E. et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 60(10), 3146\u20133152. https:\/\/doi.org\/10.1002\/art.24849 (2009).","journal-title":"Arthritis Rheum."},{"issue":"1","key":"16146_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5497\/wjp.v6.i1.1","volume":"6","author":"K Lawson","year":"2017","unstructured":"Lawson, K. Emerging pharmacological strategies for the treatment of fibromyalgia. World J. Pharmacol. 6(1), 1 (2017).","journal-title":"World J. Pharmacol."},{"issue":"1","key":"16146_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"GJ Sills","year":"2006","unstructured":"Sills, G. J. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 6(1), 108\u2013113. https:\/\/doi.org\/10.1016\/j.coph.2005.11.003 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"16146_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/ndt.s3257","volume":"4","author":"G Zareba","year":"2008","unstructured":"Zareba, G. New treatment options in the management of fibromyalgia: Role of pregabalin. Neuropsychiatr. Dis. Treat. 4(6), 1193\u20131201. https:\/\/doi.org\/10.2147\/ndt.s3257 (2008).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"16146_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DHPS.S95535","volume":"8","author":"S Bhusal","year":"2016","unstructured":"Bhusal, S., Diomampo, S. & Magrey, M. N. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug Healthc. Patient Saf. 8, 13\u201323. https:\/\/doi.org\/10.2147\/DHPS.S95535 (2016).","journal-title":"Drug Healthc. Patient Saf."},{"key":"16146_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/jpr.s7884","volume":"3","author":"CS Boomershine","year":"2010","unstructured":"Boomershine, C. S. Pregabalin for the management of fibromyalgia syndrome. J. Pain Res. 3, 81\u201388. https:\/\/doi.org\/10.2147\/jpr.s7884 (2010).","journal-title":"J. Pain Res."},{"issue":"7","key":"16146_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3899\/jrheum.141196","volume":"42","author":"LM Arnold","year":"2015","unstructured":"Arnold, L. M. et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: A randomized, Placebo-controlled Study. J. Rheumatol. 42(7), 1237\u20131244. https:\/\/doi.org\/10.3899\/jrheum.141196 (2015).","journal-title":"J. Rheumatol."},{"issue":"10","key":"16146_CR13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1185\/03007995.2014.928275","volume":"30","author":"LM Arnold","year":"2014","unstructured":"Arnold, L. M. et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: A phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr. Med. Res. Opin. 30(10), 2069\u20132083. https:\/\/doi.org\/10.1185\/03007995.2014.928275 (2014).","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"16146_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1185\/03007995.2015.1134463","volume":"32","author":"A Clair","year":"2016","unstructured":"Clair, A. & Emir, B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr. Med. Res. Opin. 32(3), 601\u2013609. https:\/\/doi.org\/10.1185\/03007995.2015.1134463 (2016).","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"16146_CR15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/j.pain.0000000000000558","volume":"157","author":"I Gilron","year":"2016","unstructured":"Gilron, I. et al. Combination of pregabalin with duloxetine for fibromyalgia: A randomized controlled trial. Pain 157(7), 1532\u20131540. https:\/\/doi.org\/10.1097\/j.pain.0000000000000558 (2016).","journal-title":"Pain"},{"issue":"11","key":"16146_CR16","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1093\/pm\/pnw098","volume":"17","author":"CE Argoff","year":"2016","unstructured":"Argoff, C. E. et al. Pregabalin improves pain scores in patients with fibromyalgia irrespective of comorbid osteoarthritis. Pain Med. 17(11), 2100\u20132108. https:\/\/doi.org\/10.1093\/pm\/pnw098 (2016).","journal-title":"Pain Med."},{"issue":"9","key":"16146_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold, L. M. et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain 9(9), 792\u2013805. https:\/\/doi.org\/10.1016\/j.jpain.2008.03.013 (2008).","journal-title":"J. Pain"},{"issue":"3","key":"16146_CR18","first-page":"502","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease, P. J. et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J. Rheumatol. 35(3), 502\u2013514 (2008).","journal-title":"J. Rheumatol."},{"issue":"3","key":"16146_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","volume":"136","author":"LJ Crofford","year":"2008","unstructured":"Crofford, L. J. et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136(3), 419\u2013431. https:\/\/doi.org\/10.1016\/j.pain.2008.02.027 (2008).","journal-title":"Pain"},{"issue":"12","key":"16146_CR20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3899\/jrheum.110569","volume":"38","author":"L Pauer","year":"2011","unstructured":"Pauer, L. et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J. Rheumatol. 38(12), 2643\u20132652. https:\/\/doi.org\/10.3899\/jrheum.110569 (2011).","journal-title":"J. Rheumatol."},{"issue":"4","key":"16146_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/art.20983","volume":"52","author":"LJ Crofford","year":"2005","unstructured":"Crofford, L. J. et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(4), 1264\u20131273. https:\/\/doi.org\/10.1002\/art.20983 (2005).","journal-title":"Arthritis Rheum."},{"key":"16146_CR22","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim, S., Yoon, B. H., Shin, I. S. & Bae, J. M. Network meta-analysis: Application and practice using Stata. Epidemiol. Health 39, e2017047. https:\/\/doi.org\/10.4178\/epih.e2017047 (2017).","journal-title":"Epidemiol. Health"},{"key":"16146_CR23","unstructured":"Higgins, J. P. T. T. J., Chandler, J., Cumpston, M., Li, T., Page, M. J. & Welch, V. A. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane 2021. Available from www.training.cochrane.org\/handbook. Accessed on February 2022."},{"key":"16146_CR24","unstructured":"Howick, J. C. I., Glasziou, P., Greenhalgh, T., Carl, H., Liberati, A., Moschetti, I., Phillips, B., Thornton, H., Goddard, O. & Hodgkinson, M. The 2011 Oxford CEBM Levels of Evidence. Oxford Centre for Evidence-Based Medicine Available at https: \/\/wwwcebmnet\/indexaspx?o=5653 (2011)"},{"issue":"6","key":"16146_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00000441-199806000-00005","volume":"315","author":"SM Harding","year":"1998","unstructured":"Harding, S. M. Sleep in fibromyalgia patients: subjective and objective findings. Am. J. Med. Sci. 315(6), 367\u2013376. https:\/\/doi.org\/10.1097\/00000441-199806000-00005 (1998).","journal-title":"Am. J. Med. Sci."},{"issue":"6","key":"16146_CR26","first-page":"1113","volume":"21","author":"J Branco","year":"1994","unstructured":"Branco, J., Atalaia, A. & Paiva, T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J. Rheumatol. 21(6), 1113\u20131117 (1994).","journal-title":"J. Rheumatol."},{"issue":"6","key":"16146_CR27","first-page":"1193","volume":"31","author":"M Rizzi","year":"2004","unstructured":"Rizzi, M. et al. Cyclic alternating pattern: A new marker of sleep alteration in patients with fibromyalgia?. J. Rheumatol. 31(6), 1193\u20131199 (2004).","journal-title":"J. Rheumatol."},{"key":"16146_CR28","unstructured":"ASTM F2706-18 STMfO-CaO-C-TSICiaVM, ASTM International, West Conshohocken, PA, 2018. Available at www.astm.org. Accessed in October, 2020."},{"issue":"4","key":"16146_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/rheumatology\/kep432","volume":"49","author":"S Straube","year":"2010","unstructured":"Straube, S., Derry, S., Moore, R. A. & McQuay, H. J. Pregabalin in fibromyalgia: Meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 49(4), 706\u2013715. https:\/\/doi.org\/10.1093\/rheumatology\/kep432 (2010).","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"16146_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.sleep.2009.01.009","volume":"10","author":"IJ Russell","year":"2009","unstructured":"Russell, I. J. et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med. 10(6), 604\u2013610. https:\/\/doi.org\/10.1016\/j.sleep.2009.01.009 (2009).","journal-title":"Sleep Med."},{"issue":"4","key":"16146_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/pmt-2016-0006","volume":"6","author":"A Okifuji","year":"2016","unstructured":"Okifuji, A., Gao, J., Bokat, C. & Hare, B. D. Management of fibromyalgia syndrome in 2016. Pain Manag. 6(4), 383\u2013400. https:\/\/doi.org\/10.2217\/pmt-2016-0006 (2016).","journal-title":"Pain Manag."},{"issue":"2","key":"16146_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane, G. J. et al. EULAR revised recommendations for the management of fibromyalgia. Ann. Rheum. Dis. 76(2), 318\u2013328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209724 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"16146_CR33","doi-asserted-by":"publisher","first-page":"6541798","DOI":"10.1155\/2020\/6541798","volume":"2020","author":"R Tzadok","year":"2020","unstructured":"Tzadok, R. & Ablin, J. N. Current and emerging pharmacotherapy for fibromyalgia. Pain Res. Manag. 2020, 6541798. https:\/\/doi.org\/10.1155\/2020\/6541798 (2020).","journal-title":"Pain Res. Manag."},{"issue":"3","key":"16146_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semarthrit.2011.06.003","volume":"41","author":"E Choy","year":"2011","unstructured":"Choy, E. et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin. Arthritis. Rheum. 41(3), 335\u2013345. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.06.003 (2011).","journal-title":"Semin. Arthritis. Rheum."},{"key":"16146_CR35","doi-asserted-by":"publisher","first-page":"7076","DOI":"10.1002\/14651858.CD007076.pub2","volume":"3","author":"RA Moore","year":"2009","unstructured":"Moore, R. A., Straube, S., Wiffen, P. J., Derry, S. & McQuay, H. J. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev. 3, 7076. https:\/\/doi.org\/10.1002\/14651858.CD007076.pub2 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1\u20132","key":"16146_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","volume":"145","author":"W Hauser","year":"2009","unstructured":"Hauser, W., Bernardy, K., Uceyler, N. & Sommer, C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin\u2014A meta-analysis of randomized controlled trials. Pain 145(1\u20132), 69\u201381. https:\/\/doi.org\/10.1016\/j.pain.2009.05.014 (2009).","journal-title":"Pain"},{"issue":"5","key":"16146_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00296-016-3468-5","volume":"36","author":"YH Lee","year":"2016","unstructured":"Lee, Y. H. & Song, G. G. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: A Bayesian network meta-analysis of randomized controlled trials. Rheumatol. Int. 36(5), 663\u2013672. https:\/\/doi.org\/10.1007\/s00296-016-3468-5 (2016).","journal-title":"Rheumatol. Int."},{"issue":"6","key":"16146_CR38","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1533-2500.2010.00441.x","volume":"11","author":"NS Roskell","year":"2011","unstructured":"Roskell, N. S., Beard, S. M., Zhao, Y. & Le, T. K. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 11(6), 516\u2013527. https:\/\/doi.org\/10.1111\/j.1533-2500.2010.00441.x (2011).","journal-title":"Pain Pract."},{"issue":"5","key":"16146_CR39","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.clinthera.2012.03.003","volume":"34","author":"LM Arnold","year":"2012","unstructured":"Arnold, L. M. et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin. Ther. 34(5), 1092\u20131102. https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.003 (2012).","journal-title":"Clin. Ther."},{"key":"16146_CR40","first-page":"163","volume":"1","author":"R Poluha","year":"2018","unstructured":"Poluha, R. & Grossmann, E. Does pregabalin improve sleep disorders in fibromyalgia?. Br. J. Pain S\u00e3o Paulo 1, 163\u2013166 (2018).","journal-title":"Br. J. Pain S\u00e3o Paulo"},{"issue":"7","key":"16146_CR41","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner, J. & Targum, S. D. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7), 28\u201337 (2007).","journal-title":"Psychiatry (Edgmont)"},{"issue":"6","key":"16146_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar4395","volume":"15","author":"A Vincent","year":"2013","unstructured":"Vincent, A. et al. Beyond pain in fibromyalgia: Insights into the symptom of fatigue. Arthritis Res. Ther. 15(6), 221. https:\/\/doi.org\/10.1186\/ar4395 (2013).","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"16146_CR43","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1589\/jpts.26.1561","volume":"26","author":"M Vural","year":"2014","unstructured":"Vural, M. et al. Evaluation of the effectiveness of an aerobic exercise program and the personality characteristics of patients with fibromyalgia syndrome: A pilot study. J. Phys. Ther. Sci. 26(10), 1561\u20131565. https:\/\/doi.org\/10.1589\/jpts.26.1561 (2014).","journal-title":"J. Phys. Ther. Sci."},{"issue":"10","key":"16146_CR44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/PHM.0000000000000485","volume":"95","author":"AS Kaleth","year":"2016","unstructured":"Kaleth, A. S., Slaven, J. E. & Ang, D. C. Determining the minimal clinically important difference for 6-minute walk distance in fibromyalgia. Am. J. Phys. Med. Rehabil. 95(10), 738\u2013745. https:\/\/doi.org\/10.1097\/PHM.0000000000000485 (2016).","journal-title":"Am. J. Phys. Med. Rehabil."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16146-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16146-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16146-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:09:43Z","timestamp":1669349383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16146-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16146"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16146-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12148"}}